Henlius Begins Phase I Trial for Biosimilar HLX15 Targeting Multiple Myeloma
Shanghai Henlius Biotech (HKG: 2696) has announced the dosing of the first subject in a...
Shanghai Henlius Biotech (HKG: 2696) has announced the dosing of the first subject in a...
China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical clearance from the National Medical...
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving approval from the US FDA to...
China’s Betta Pharmaceuticals (SHE: 300558) has announced receiving clinical trial approval from the US FDA...
China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has announced receiving approval from the US...
China-based Luye Pharma Group (HKG: 2186) has announced receiving approval from the Center for Drug...
Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that the clinical trial filing for...
Hangzhou-based HealZen Therapeutics has announced receiving approval from the National Medical Products Administration (NMPA) to...
Shanghai-based JS InnoPharm Ltd has announced the initiation of a Phase I clinical study by...
Hangzhou-based clinical stage gene therapy firm Exegenesis Bio has announced receiving approval from the US...
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving Investigational New Drug (IND) approval from...
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
CNBG-Virogin Biotech (Shanghai) Co., Ltd has announced obtaining clinical trial approval from the National Medical...
China-based Harbour BioMed (HKG: 2142) has announced receiving approval from the US FDA to initiate...
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced the first subject dosing in...
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced receiving approval from the National...
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving approval from the National...
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the dosing of four healthy subjects in...
Xiamen-based Amoytop Biotech Co. Ltd has announced receiving clinical trial approval from China’s National Medical...